ESTRO 2025 - Abstract Book

S220

Brachytherapy - Gynaecology

ESTRO 2025

Conclusion: Single-session HDR brachytherapy with mid-treatment imaging allowed for dose monitoring and demonstrated minor dosimetric variations in target volumes and OARs, with the majority of patients maintaining adherence to dose constraints. These findings support the feasibility of single-application HDR brachytherapy for LACC.

Keywords: Cervical; brachytherapy; HDD

763

Digital Poster Experience on the use of the Venezia® applicator for brachytherapy of vaginal tumours in 19 patients

Sophie Renard 1 , Emma Agnoux 1 , Claire Charra-Brunaud 2 , Jean-François Py 2 , Emilie Meknaci 2 , Didier Peiffert 2 , Marie Bruand 2 1 radiotherapy, Institut de Cancérologie de Lorraine, NANCY, France. 2 radiotherapy, Institut de Cancérologie de Lorraine, Nancy, France Purpose/Objective: Primary and metastatic vaginal tumours are rare and require precise treatment approaches. For optimal delineation of target volumes, especially in tumours with deeper paravaginal extension, MRI-compatible brachytherapy applicators are advantageous. While some applicators are dedicated to endovaginal use, few options allow interstitial implantation suitable for extensive disease. This study reports our experience using the Venezia® applicator, initially designed for cervical cancer, for the brachytherapy management of primary and secondary vaginal tumours. Material/Methods: Treatment details and dosimetric data were retrospectivly collected from nineteen patients treated from august 2020 to octobre 2024 with the Venezia® applicator for vaginal tumours.Target volumes (High Risk (HR) CTV and